anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In patients with uncomplicated essential hypertension not on diuretic therapy, the recommended initial dose is 10 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 20 mg to 40 mg per day administered in a single daily dose. The antihypertensive effect may diminish toward the end of the dosing interval regardless of the administered dose, but most commonly with a dose of 10 mg daily. This can be evaluated by measuring blood pressure just prior to dosing to determine whether satisfactory control is being maintained for 24 hours. If it is not, an increase in dose should be considered. Doses up to 80 mg have been used but do not appear to give greater effect. If blood pressure is not controlled with lisinopril alone, a low dose of a diuretic may be added. Hydrochlorothiazide, 12.5 mg has been shown to provide an additive effect. After the addition of a diuretic, it may be possible to reduce the dose of lisinopril tablets.
Born in the years 2005-2009 with birth gestational age ≥ 38 weeks gestation and birth weight appropriate for term gestation (n=10) matched by age/sex/race to participating cohort children with no history of respiratory difficulty suggesting hypoxic exposure. Children will undergo Magnetic Resonance Imaging and Cognitive Performance Testing.
This group received approximately 12 sessions of the telehealth intervention. The intervention consisted of parent-therapist conversations via telehealth to increase child function and participation.
BACKGROUND: Adult-onset Still's disease (AOSD) is a rare yet well-documented polygenic and systemic autoinflammatory disease characterized by recurrent spiking fever, transient skin rash, arthralgia, and sore throat. Traditional Chinese medicine (TCM) holds a significant role in complementary and alternative medicine. This study presents a unique case of a female AOSD patient with concurrent Qi and fluid deficiency syndrome who received combined treatment with formulated Zhu Ye Shi Gao Decoction (ZYSGD).
CASE PRESENTATION: In this case, a 28-year-old female patient presented with a 15-day history of fever and skin rash accompanied by sore throat, fatigue, myalgia, and arthralgia. Additionally, leucocytosis, aminotransferase abnormalities, and elevated inflammatory factor levels were observed. Infectious diseases, solid tumors, and hematological disorders were all ruled out. Anti-infective treatments proved ineffective, leading to the final diagnosis of AOSD. Glucocorticoid therapy provided only partial relief. Consequently, formulated ZYSGD and hepatoprotective drugs were added to the glucocorticoid treatment. Subsequently, the patient's symptoms and inflammatory biomarkers showed improvement. After discharge, the patient's condition remained stable while continuing the formulated ZYSGD in combination with 4 mg of Medrolol (qd) during a 10-month follow-up period.
CONCLUSION: This case report suggests that formulated ZYSGD could be a viable option for complementary and alternative therapy for late-stage AOSD, especially in cases involving both Qi and body fluid imbalances.
Following insertion of at least 20 cm of the guidewire into the right subclavian vein, the probe is shifted to the right supraclavicular fossa to scan the right internal jugular vein in order to exclude malposition of the guidewire. The probe is then tilted in a caudal direction to obtain a view of the guidewire within the superior vena cava. Misplaced guidewires will be corrected under real-time ultrasound guidance.
Patients who will not receive any intervention before prostate cancer surgery. Then patients will have radical laparoscopic prostatectomy, after which (after 2 and 6 weeks) they receive psychological consultation, nursing consultation (immediately after surgery) and physiotherapeutic consultation (supervised exercises - meeting twice a week with a physiotherapist, after 2 weeks from surgery for 3 months - 24 interventions, patients for three months additionally perform the recommended exercises 3 times a day at home for 3 months on their own). Physiotherapeutic consultation 6 months after surgery.
The utility model relates to a medicinal plaster for cleaning an anus and protecting a pudendum, which comprises a basal lining, pressure-sensitive adhesive on the lower part of the basal lining, and a separate paper. Medicine adhesive is arranged on the basal lining, and a slow release layer with a filtering function is also arranged on the upper part of the medicine adhesive. The medicinal plaster for cleaning an anus and protecting a pudendum adopts that an anus part uses medicine, and volatile medicine effect gas is fully used to disinfect and sterilize to an anus and a pudendum. The medicinal plaster for cleaning an anus and protecting a pudendum plays the functions of health care, prevention, and treatment. The slow release of the medicine adhesive can be kept. The medicinal plaster for cleaning an anus and protecting a pudendum can be very conveniently used for the combination of a sanitary towel or underpants. The medicine dosage of the medicinal plaster for cleaning an anus and protecting a pudendum is less than the medicine dosage of a medicine towel, and the function of the medicinal plaster for cleaning an anus and protecting a pudendum is larger than a sanitary towel for haemorrhoids. The medicinal plaster for cleaning an anus and protecting a pudendum can not cause direct encroachment to pudendumda and anuses, and the cost of the medicinal plaster for cleaning an anus and protecting a pudendum is lower.
PURPOSE OF REVIEW: The burden of epilepsy is complex and consists of elements directly related to acute seizures as well as those associated with living with a chronic neurologic disorder. The purpose of this systematic review was to characterize short-term burdens of seizures and to explore the potential value of acute treatments to mitigate these burdens apart from reducing the risk of status epilepticus.
RECENT FINDINGS: A systematic literature search was conducted using PubMed to identify articles published from January 1, 2017, to June 22, 2023, that described short-term burdens and acute treatments of seizures. Primary outcomes included those related to short-term burdens of seizures and the benefits of acute treatments to reduce short-term burdens. Of the 1332 articles identified through PubMed and 17 through other sources, 27 had relevant outcomes and were included in the qualitative synthesis. Seizure emergencies negatively affected short-term quality of life and the ability to conduct normal daily living activities and were associated with physical (injury) and financial (emergency transport, hospitalization) burdens. The use of acute treatment was associated with a rapid return (≤ 1 h) to normal function/self for both patients and caregivers and potentially lower healthcare utilization and costs. Seizure action plans may improve knowledge and comfort with seizure care, empowering patients and caregivers. The short-term burden of seizures can create a substantial negative impact on patients and caregivers. Acute treatments may reduce the short-term burdens of seizures in addition to their well-described role to reduce seizure activity and the risk for status epilepticus.
The invention relates to a CTL (cytotoxic lymphocyte) epitope polypeptide of vascular endothelial growth factors and application of the CTL epitope polypeptide. Amino acid sequences of the CTL epitope polypeptide are shown as SEQ ID NO.3; a derivative sequence or a plurality of derivative sequences of amino acid is substituted, deleted, displaced, inserted and/or added to the CTL epitope polypeptide on the basis of the amino acid sequences show as the SEQ ID NO.3. The invention further provides vaccine. The vaccine comprises the CTL epitope polypeptide of the vascular endothelial growth factors and an adjuvant. The adjuvant is gp96 protein. The CTL epitope polypeptide, the application and the vaccine have the advantages that the adjuvant and the CTL epitope polypeptide of the vascular endothelial growth factors are matched with each other, accordingly, the immunity can be improved, tumor treatment effects can be obviously improved, and the like.
Patients exclusively treated with a single complex-containing (CC) formulation (onabotulinumtoxinA or abobotulinumtoxinA). A maximum of 328 patients will be enrolled in this group.
The World Health Organization Regional Office for Africa (WHO/AFRO) faces members who encounter annual disease epidemics and natural disasters that necessitate immediate deployment and a trained health workforce to respond. The gaps in this regard, further exposed by the COVID-19 pandemic, led to conceptualizing the Strengthening and Utilizing Response Group for Emergencies (SURGE) flagship in 2021. This study aimed to present the experience of the WHO/AFRO in the stepwise roll-out process and the outcome, as well as to elucidate the lessons learned across the pilot countries throughout the first year of implementation. The details of the roll-out process and outcome were obtained through information and data extraction from planning and operational documents, while further anonymized feedback on various thematic areas was received from stakeholders through key informant interviews with 60 core actors using open-ended questionnaires. In total, 15 out of the 47 countries in WHO/AFRO are currently implementing the initiative, with a total of 1,278 trained and validated African Volunteers Health Corps-Strengthening and Utilizing Response Groups for Emergencies (AVoHC-SURGE) members in the first year. The Democratic Republic of Congo (DRC) has the highest number (214) of trained AVoHC-SURGE members. The high level of advocacy, the multi-sectoral-disciplinary approach in the selection process, the adoption of the one-health approach, and the uniqueness of the training methodology are among the best practices applauded by the respondents. At the same time, financial constraints were the most reported challenge, with ongoing strategies to resolve them as required. Six countries, namely Botswana, Mauritania, Niger, Rwanda, Tanzania, and Togo, have started benefiting from their trained AVoHC-SURGE members locally, while responders from Botswana and Rwanda were deployed internationally to curtail the recent outbreaks of cholera in Malawi and Kenya.
PROBLEM TO BE SOLVED: To obtain cleaning material for an oral cavity which can conveniently remove dirt in month in a short time, particularly dental plaque and stain dirt adhering to the surface of teeth, by simply wipping out by impregnating a water-insoluble material with a specific liquid composition or allowing the composition to adhere to the material. SOLUTION: The liquid composition (A) is obtained by formulating (i) a substance (e.g. calcium chloride) for supplying calcium ion from which 0.01-100mM of calcium ion can be supplied, (ii) a substance (e.g. potassium monohydrogenphosphate) for supplying orthophosphric acid ion from which 0.1-3000mM of orthophosphoric acid ion can be supplied, (iii) 0.1-50wt.% of a substance (e.g. lactic acid) having buffer capacity in acidic regions and, when necessary, (iv) menthol, caking additives, enzymes, surfactants, humectants, water-insoluble abrasives, antiseptics, coloring agents, perfumes and sweetenings and regulating it to pH3-6.5. The oral cleaning material is obtained by impregnating (B) a water-insoluble material (e.g. cotton woven cloth) with the A component of allowing the A component to adhere to the water-insoluble material.
A method and a device are used for determining a characteristic value for the perfusion of modified, in particular pigmented tissue regions in organs of living beings, for example the skin. By means of a laser flowmeter, a first volumetric flow rate and a second volumetric flow rate of the blood are determined at a first measurement point and at a second measurement point, respectively within the modified tissue region and within the surrounding, unmodified tissue region, in each case as a measurement profile of a volumetric flow rate signal as a function of time. A wavelet analysis of each of the measurement profiles is then carried out as a three-dimensional representation of the signal intensity over a frequency or scaling axis and time. The profile of a vasomotion energy over the frequency or scaling axis is subsequently determined for each of the measurement profiles subjected to the wavelet analysis, the vasomotion energy being the integral of the signal intensity with respect to time for a particular frequency or scaling value. Next, the profile of the vasomotion energy of the second measurement profile is subtracted from the profile of the vasomotion energy of the first measurement profile, so as to form a difference profile. The difference profile is then integrated in order to obtain the characteristic value.
Methods, systems, and computer program products for providing a policy-based information storage management system for digital assets are provided. The storage management system includes multiple physical storage subsystems, each with deterministic storage characteristics. A method includes receiving a data item related to a subject and looking up a record for the subject. The record identifies corresponding digital assets that are stored in the storage subsystems. The method also includes applying a policy to the corresponding digital assets based upon the data item. The method further includes determining a subset of the digital assets in the record that are relevant to the data item. The relevance determination is made in response to application of the policy. The method also includes migrating the relevant digital assets to at least one designated storage subsystem, based upon corresponding storage characteristics, for expediting access to the relevant digital assets.
Semi-structured interviews were conducted for the qualitative research. In addition, a driving habits questionnaire was administered. To complete this questionnaire, medical data from the PROOF cohort were collected.The PROOF cohort is a prospective study for which enrollment began in 2001. The main objective is to evaluate the predictive value of Autonomic Nervous System (ANS) activity and its decline during follow-up on the occurrence of serious and cerebral events, and on all-cause mortality, in a general population of subjects of homogeneous age. Participants were included in the study if they were 65 years of age (plus or minus 2 years) at the time of inclusion and registered on the electoral list of the city of St Etienne, had not had a previous myocardial infarction or stroke and were non-insulin dependent.
FIELD: chemistry. ^ SUBSTANCE: compounds of the invention can be used for treating or preventing diseases and conditions, mediated by peroxisome proliferator activated gamma receptor (PPAR). In formula (I) W represents a COOH group or -COOC-C1-C4alkyl; Y represents NH; Z represents S or O; X represents O; R1-R6 each independently represents a hydrogen atom or substitute, chosen from a group consisting of: C1-C4-alkyl, thienyl or phenyl, where phenyl is optionally substituted with one or more substitutes, independently chosen from a group consisting of C1-C4-alkyl, C1-C4-alkoxy, a halogen atom; -NO2 and -CN; A represents C1-C4-alkyl, -N(C1-C4-alkyl)-CO-C3-C7-cycloalkyl, aryl, chosen from a group consisting of phenyl, naphthyl, or heteroaryl, chosen from a group consisting of oxazolyl, isoxazolyl, thienyl, pyridyl, thiazolyl, thiadiazolyl, benzo[b]thienyl, imidazolyl, indolyl and carbazolyl, where aryl and heteroaryl are substituted or not substituted with one or more substitutes, independently chosen from a group consisting of C1-C4-alkyl, C1-C4-alkoxy, phenyl and a halogen atom; and n is an integer from 0 to 4. The invention also relates to a pharmaceutical composition, containing the invented compound as an active component, use of the compounds to make a medicinal agent, and method of treatment. ^ EFFECT: obtaining new biologically active compounds. ^ 22 cl, 6 ex
The invention relates to medicine, namely, to the solutions used for hemostasis. The hemostatic agent, which represents a polyammonia methanediamine chloride of the general formula   
where: n = 1-20, m = 1-10, at that n x m ¥ 8.  The hemostatic agent may be applied in the form of a 0.01-10% aqueous solution. An aqueous solution of the preparation can be used for impregnation of materials used for bleeding arrest, suture material, bandaging material. The hemostatic agent may be used in the composition of a retraction cord, adhesive pastes, vaginal and rectal suppositories, creams, gels, as well as used with microchips that provide slow release of the preparation. The preparation can also be used in eye drops, eye ointments, and lubricants applied to the surface of the catheter. The drug can be used in endodontic treatment, may be injected into a polymer sealer for root canal obturation, as well as locally - by means of electrophoresis. The hemostatic agent may be used in conjunction with a gel based on aluminum sulphate or silver solution, and also with a polysaccharide haemostatic system. An efficient haemostatic preparation ensuring a significant analgetic effect is developed.
The early screening group will be screened by a 75g 2-hour oral glucose tolerance test (OGTT) at 18-20 weeks of gestational age (GA). The time of early screening and intervention will be 6-8 weeks earlier than that of standard screening and intervention.
Given 2 bottles of placebo. They will be instructed to take 1 of each pill for the seven days prior to their surgery.
An expected outcome data system stores data representing a plurality of different expected outcomes of patient care and treatment for use in providing healthcare to a patient. An acquisition processor acquires data representing an expected outcome of treatment associated with a medical problem for storage in a repository. A repository, electrically coupled to the acquisition processor, includes data representing a plurality of different expected outcomes; an individual expected outcome has an expected outcome name and is characterized by expected outcome attributes; an individual expected outcome has a plurality of attribute properties determining how an expected outcome attribute is represented. Expected outcome attributes include a focus term indicating a topic of an expected outcome, an expected outcome likelihood term indicating an assessment of likelihood of the associated corresponding expected outcome, and a client term indicating at least one target person for care. The attribute properties include a format attribute property indicating a format constraint of an expected outcome attribute and a content attribute property indicating a content constraint of an expected outcome attribute. A retrieval processor, electrically coupled to the repository, retrieves data representing at least one expected outcome from the repository.
INTRODUCTION: Thoracic endovascular aortic repair (TEVAR) has gained preference over open surgical repair (OSR) as the intervention of choice for patients with descending thoracic aortic aneurysm (DTA). This study aimed to compare the outcomes of patients with DTA undergoing OSR and TEVAR with contemporary findings.
EVIDENCE ACQUISITION: A comprehensive search of MEDLINE and EMBASE databases was conducted to identify relevant randomized controlled trials or studies utilizing propensity-score analysis or reporting risk-adjusted outcomes. The search was performed up until March 2023.
EVIDENCE SYNTHESIS: Eight studies met the inclusion criteria, including 4 studies using propensity-score matching and four studies reporting risk-adjusted outcomes, comprising 14,873 patients with DTA undergoing OSR (N.=10,882) and TEVAR (N.=3991). Operative mortality was similar between the two interventions (odds ratio 0.92, 95% CI 0.70-1.21, P=0.57, I2=0%). However, overall long-term mortality was significantly higher after TEVAR compared to OSR (Hazard Ratio [HR] 1.30, 95% CI 1.05-1.59, P=0.01, I2=0%). Phase-specific analysis revealed comparable risks of mortality within 1 year and between one and two years after interventions, while the risk of mortality was significantly higher after TEVAR compared to OSR beyond two years (HR 1.77, 95% CI, 1.19-2.63, P=0.01. I2=0%).
CONCLUSIONS: This study demonstrated comparable operative mortality between OSR and TEVAR, but higher long-term mortality associated with TEVAR in patients with DTA. The phase-specific analysis highlighted the survival advantage of OSR beyond 2 years. These findings suggest a need for reconsidering OSR indications in the management of DTA.
Orthognathic surgery is usually the final phase of treatment for patients with cleft lip and palate (CLP). More than 25% of patients with CLP develop a significant maxillary hypoplasia that requires surgical intervention, and maxillary osteotomy is, therefore, most commonly performed for these patients. If the sagittal discrepancy is too large or if there are associated mandibular deformities (e.g., asymmetries, canting of the mandibular occlusal plane), a simultaneous setback of the mandible is performed. The bilateral sagittal split osteotomy (BSSO) has become the preferred mandibular osteotomy in many centers for the treatment of mandibular deformities. Nevertheless, this treatment is known to give rise to various complications; sensory disturbance of the inferior alveolar nerve (IAN) is probably the most common one with the incidence ranging from 8% to 85%. Such sensory disturbances may affect patients' quality of life due to the difficulties in speech, eating and drinking. Patients may also complain about the inability to assess tactile stimuli such as putting on lipstick, shaving or kissing, which may lead to psychological and social issues.

IAN disturbance is believed to be caused by iatrogenic injury to the nerve including excessive nerve manipulation, nerve laceration, fixation of segments by incorrect placement of position screws, large mandibular movement and bad splits. Identification of risk factors for IAN disturbance after BSSO can help clinician to prevent it and raise the satisfaction level of patients. It is generally thought that the injury to IAN inside the mandibular ramus and body during surgery are highly correlated to variations in preoperative anatomy (ie, patient-related factors). Previous computed tomography (CT) studies have reported the anatomical variations including the thickness and length of ramus, the position and bone density of inferior alveolar nerve canal (IAC) and thickness of buccal and lingual cortical plate. However, few studies tried to identify surgery-related factors such as types of BSSO, extent of surgical correction, extent of split, concomitant genioplasty or third molar extraction. Furthermore, most of the studies were retrospective in design or had limited number of patients to conduct multivariate analysis to recognize the influences of patient- and surgery-related risk factors on IAN disturbance. Moreover, heterogeneity of the assessment timing and methods for IAN disturbance in previous studies prevented from overall assessment of the degree of IAN recovery. We therefore aim to (1) determine the incidence of IAN injury after BSSO, (2) identify the risk factors associated with such injuries, and (3) understand the consequences of such injuries including the degree of neurologic recovery by performing a prospective, longitudinal study.